Development of a personalized immune-modulating therapy for patients with atopic dermatitis: evaluation of clinical efficacy of autologous immunoglobulin therapy for recalcitrant atopic dermatitis: a randomized, double-blind, placebo-controlled study

Ajou University Hospital0 个研究点目标入组 51 人开始时间: 待定最近更新: 2019年3月11日

适应症

试验速览

暂无简介。

•1. Suitability of autologous blood donation criteria
•1) Determine blood volume: up to 15% of the estimated blood volume (EBV) (Blood volume is 10 ml/kg;minimall body weight = 32Kg )
•2) Blood Platelet: = 150,000/?
•3) Hemoglobin : = 11 g/dL
•4) Blood pressure: Systolic blood pressure 90 ~ 179 mmHg,
•Diastolic blood pressure < 100mmHg
•5) Pulse : 50 ~ 100 (time/minute)
•6) Temperature := 37.5?
•2. Current standard medical therapies more than 2 months and moderate-to-severe atopic dermatitis)
•3. =10% lesion body surface area (BSA) of atopic dermatitis involvement in area

•Exclusion criteria
•1) Patients under the age of 13 year.
•2) Patients who are unable to agree on their own (emergency patients, patients with mental disability, patients with limited capacity to consent due to stroke or delirium caused by diabetes).
•3) Patients with severe disease whose expected survival duration is less than 3 months.
•4) Pregnancy or planned pregnancy within 1 year
•5) Skin condition not appropriate for blood sampling and transfusion
•6) The standardized clinical severity scoring system for atopic deramtitis (SCORAD) values <25 (Mild atopic dermatitis)

发起方

Ajou University Hospital